Results 71 to 80 of about 34,076,848 (256)
Review of the Molecular and Developmental Basis of Myhre Syndrome, Bench Research
American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.ABSTRACT Myhre syndrome (MS) is a connective‐tissue disorder within the acromelic dysplasia spectrum. It is characterized by congenital craniofacial, skeletal, cutaneous anomalies, respiratory, cardiovascular along with intellectual disability, deafness, and progressive fibrosis.
Camille Viaut, Valerie Cormier‐Daire
wiley +1 more source
The Angiotensin II Type 2 Receptor for Pain Control [PDF]
, 2014 All well-known deleterious effects of angiotensin (Ang) II, including vasoconstriction, inflammation, water and salt retention, and vascular remodeling, are mediated via its type 1 (AT(1)) receptor.
Anand, P, Danser, Jan
core +2 more sources
BMC NeuroscienceBackground Astrocytes are the most abundant cell type of the central nervous system and are fundamentally involved in homeostasis, neuroprotection, and synaptic plasticity.
Daniel Navin Olschewski +12 more
doaj +1 more source
Scientific Reports, 2017 Rivaroxaban is an oral direct factor Xa inhibitor approved for the treatment of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation. Despite its efficacy, rivaroxaban therapy results in adverse effects and complications,
Dan Yang +5 more
doaj +1 more source
The 9+ month marathon: How pregnancy may have shaped human endurance capacities
The Anatomical Record, EarlyView.Abstract Anthropology has long considered the evolution of our uniquely human endurance capacities to be the result of selection upon anatomical and physiological features imposed by the demands of thermoregulation and resource acquisition, particularly during the demands of persistence hunting. Research has focused on the anatomical changes present in
Cara Ocobock
wiley +1 more source
Development of selective non-peptide angiotensin II type 2 receptor agonsists
, 2010 The development of the first drug-like selective angiotensin II type 2 (AT(2)) receptor agonist (22) derived from the non-selective angiotensin II type 1 (AT(1)) receptor/AT(2) receptor agonist L-162,313 is presented.
Mathias Alterman, Alterman, Mathias,
core +1 more source
Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis
Arthritis &Rheumatology, EarlyView.Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm +2 more
wiley +1 more source
В мире научных открытий, 2016 The article discusses the effectiveness of 3-month therapy with angiotensin converting enzyme inhibitors fosinopril receptor and antagonists of the angiotensin II valsartan to achieve target BP(
Zarina Vyacheslavovna Bitarovа +3 more
doaj +1 more source
Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. [PDF]
, 2005 BACKGROUND: Morbidity in COPD results from a combination of factors including hypoxia-induced pulmonary hypertension, in part due to pulmonary vascular remodelling. Animal studies suggest a role of angiotensin II and acute studies in man concur.
Shakur, B Haleema +17 more
core +2 more sources
Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis
Arthritis &Rheumatology, EarlyView.Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo +7 more
wiley +1 more source